InvestorsHub Logo
Followers 1
Posts 85
Boards Moderated 0
Alias Born 01/24/2018

Re: melody432 post# 6333

Thursday, 08/27/2020 7:52:47 PM

Thursday, August 27, 2020 7:52:47 PM

Post# of 7490
I agree. Early stage biotechs are not valued by bottom line but more on product and pipeline. If the burn rate stays high and the have to dilute that could be a problem in the future, but even that won’t be a big problem if it’s to fund something very promising.
The good news is RCEL is getting noticed and as you mentioned volume has picked up dramatically. Quarterly sales comparisons should be favorable. I think one piece of positive news and it will pop. When that is, I haven’t a clue but I’m confident it will happen
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RCEL News